肺癌低剂量CT筛查:二十年研究证据
本文综述了自20世纪90年代中后期以来低剂量CT筛查高危人群肺癌的证据,指出该筛查能早期检出肺癌并降低肺癌死亡风险,目前已成美国推荐临床服务并受指南与报销要求规范,本文还总结了指南标准及可能改善筛查的进展。
要点
- 低剂量CT筛查高危人群可早期检出肺癌并降低肺癌死亡风险。
- CT筛查在美国已成为推荐临床服务,受指南与报销要求规范。
- 需更好了解研究试验之外临床实践中的筛查表现。
核心结论
- 自20世纪90年代中后期积累的证据表明,对高危患者进行低剂量CT筛查可实现肺癌早期检出并降低肺癌死亡风险。
- CT筛查目前是美国推荐的临床服务,受旨在规范实践并优化获益风险平衡的指南与报销要求约束。
研究设计与样本
- 本文为综述,总结CT筛查有效性证据并描述现行指南与标准,同时概述可能改善CT筛查的潜在进展。
- 原文讨论了需更好了解研究试验之外临床实践中的筛查表现。
临床应用与阅片要点
- 原文指出CT筛查是美国推荐的临床服务,受指南与报销要求规范。
- 原文提出需更好了解研究试验之外临床实践中的筛查表现。
局限性
- 原文提出需更好了解研究试验之外临床实践中的筛查表现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Lung cancer remains the overwhelmingly greatest cause of cancer death in the United States, accounting for more annual deaths than breast, prostate, and colon cancer combined. Accumulated evidence since the mid to late 1990s, however, indicates that low-dose CT screening of high-risk patients enables detection of lung cancer at an early stage and can reduce the risk of dying from lung cancer. CT screening is now a recommended clinical service in the United States, subject to guidelines and reimbursement requirements intended to standardize practice and optimize the balance of benefits and risks. In this review, the evidence on the effectiveness of CT screening will be summarized and the current guidelines and standards will be described in the context of knowledge gained from lung cancer screening studies. In addition, an overview of the potential advances that may improve CT screening will be presented, and the need to better understand the performance in clinical practice outside of the research trial setting will be discussed. © RSNA, 2020.
引用
- Gierada DS, Black WC, Chiles C, et al. Low-Dose CT Screening for Lung Cancer: Evidence from 2 Decades of Study. Radiol Imaging Cancer. 2020. PMID: 32300760. doi:10.1148/rycan.2020190058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。